Incretin Physiology and Beta-cell Function Before and After Weight-loss
Incretin Physiology and Beta-cell Function Before and After Weight-loss
To evaluate the impact of laparoscopic adjustable gastric banding (LAGB) on beta-cell
 function, insulin sensitivity, incretin function, postprandial secretion of incretin hormones
 (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) in
 morbidly obese patients and to describe the pathophysiological mechanisms involved in the
 amelioration of glucose homeostasis during long-term weight loss.
Morbid obesity represents a serious health issue in Western countries, with a rising
 incidence and a strong association with increased mortality and serious co-morbidities, such
 as diabetes. Surgical interventions, such as laparoscopic gastric banding have been developed
 with the aim of providing a laparoscopic placed device that is safe and effective in
 generating substantial weight loss. By investigation of the incretin effect, the secretion of
 GIP and GLP-1, the insulin response and sensitivity and the beta-cell responsiveness to
 glucose in 10 obese patients without type 2 diabetes before and after laparoscopic gastric
 banding the aim of this project is describe the pathophysiological mechanisms involved in the
 amelioration of glucose homeostasis during long-term weight loss.
Inclusion Criteria:

 -  Caucasians without type 2 diabetes mellitus

 -  Normal OGTT (75 g of glucose) according to WHO's criteria

 -  Patients fulfilling the criteria for laparoscopic gastric banding

 -  Normal Hemoglobin

 -  Informed consent

 Exclusion Criteria:

 -  Liver disease (ALAT > 2 x normal level)

 -  Nephropathy (s-creatinin > 130 µM or albuminuria)

 -  Relatives (parents/siblings) with T2DM

 -  Medical treatment witch cannot be stopped for 12 hours